FDA’s Path Toward Diversity in Clinical Trials: The DEPICT Act and Sponsor Responsibility

The Food and Drug Administration (FDA) has been involved in evolving legislation which supports greater diversity in clinical trials. Additionally, the FDA has written numerous guidances which are further testament to the commitment that the FDA holds in seeing a more diverse clinical trial population. Notwithstanding, there is work to be done in this sector, and with the introduction of the DEPICT Act in early 2022 and its passage in December 2022, the inclusion of sponsors in the diversity conversation will catalyze further change. This article covers recommendations for the facilitation of the requisites of the DEPICT Act as well as recognition of some of the challenges ahead. Download now to learn more.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.


  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the phone number you would like to be contacted at.

  • Please enter the e-mail address you would like to be contacted at.

  • By submitting this form, you consent to Pharmaceutical Outsourcing storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.